ctos (pioglitazone) is a drug developed by Takeda Pharmaceuticals for the treatment of type-2 diabetes, a condition where the body does not efficiently produce insulin and cannot effectively regulate sugar in the blood. When the drug was first made available to the public in 1999, it was well received and quickly became popular among patients and doctors. By 2009, sales of Actos rose to $3.4 billion.
The U.S. Food and Drug Administration (FDA) issued a warning in September of 2010 about Actos and its link to bladder cancer after reviewing data from a ten-year study conducted by Takeda Pharmaceutical Company, the drug manufacturer. When results of another study on Actos by the French government also found a link between Actos and bladder cancer in June of 2011, regulators in France and Germany issued an Actos recall, pulling the drug from the market. The FDA mandated that information about the increased risk of bladder be added to the label of the drug and advised that Actos not be prescribed to people with bladder cancer or a history of bladder cancer.
Many Actos users who developed bladder cancer have filed lawsuits against Takeda since the connection between the drug and bladder cancer came to light. Timothy Litzenburg was a member of the trial team for six of the seven Actos trials in the mass tort litigation. Mr. Litzenburg has helped secure several million and multi-million dollar verdicts on behalf of Actos bladder cancer victims. Our firm is uniquely positioned to fight for justice on your behalf.
If you began taking Actos prior to June 2011 for the treatment of type 2 diabetes and you were later diagnosed with bladder cancer, contact us at 804.466.4412. You may be eligible for compensation.